ZOFRAN is indicated for the prevention of nausea and vomiting associated with:
- highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m2
- initial and repeat courses of moderately emetogenic cancer chemotherapy
- radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen
ZOFRAN is also indicated for the prevention of postoperative nausea and/or vomiting.
Short-acting, lipophilic sedative/hypnotic; causes global CNS depression, presumably through agonist actions on GABAa receptors